美女免费一级视频在线观看

    • <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      Deals:
      




      AbbVie announced it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion.
      




      TransDigm bought Simmonds, a proximity sensor maker, for $765 million. 
      




      Shionogi and BioVersys agreed to a deal for an antibiotic for lung disease in a deal worth up to $614 million.
      




      Longevity biotech Calico spent $25 million in cash to license therapeutic candidates targeting the interleukin-11 protein from China’s Mabwell.
      




      India’s Torrent Pharmaceuticals is acquiring a 46.39% controlling stake in JB Chemicals and Pharmaceuticals from KKR and plans to merge the two drugmakers.
      




      Concentra Biosciences bought antibody biotech IGM Biosciences for $1.25 per share.
      




      Medicus Pharma announced a definitive agreement to acquire Antev.
      




      Neurizon Therapeutics and Elanco Animal Health entered into an exclusive global licensing agreement.
      




      Verrica Pharmaceuticals unveiled an amendment to the collaboration and license agreement with Torii Pharmaceutical.
      




      Nanox announced a clinical and educational collaboration with Keiser University that makes advanced 3D imaging technology accessible to students.
      




      FDA:
      




      Unicycive Therapeutics’ phosphate binder drug received a complete response letter from the FDA.
      




      The agency accepted Allergan Aesthetics’ premarket approval application for Skinvive by Juvederm.
      




      Takeda received FDA approval of Gammagard Liquid ERC.
      




      FDA granted priority review for Merck’s Winrevair (sotatercept-csrk) to update its label based on results from its ZENITH trial.
      




      Regeneron’s Lynozyfic (linvoseltamab-gcpt) received FDA accelerated approval for treatment of relapsed or refractory multiple myeloma.
      




      Funding rounds:
      




      ANV assembled a $200 million fund to support Japanese biotech innovation.
      




      ArriVent BioPharma proposed a $75 million public offering.
      




      The NATO Innovation Fund co-led a $35 million fundraising round for Portal Biotech.
      




      Syntis Bio raised a $33 million Series A funding round.
      




      Circulate Health raised $12 million in seed funding led by Khosla Ventures.
      




      Biofrontera unveiled a major restructuring of its relationship with Biofrontera AG backed by an $11 million investment.
      




      Layoffs:
      




      Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which will take effect on August 22.
      




      Bristol Myers Squibb is letting go of 68 more employees at its Lawrenceville, New Jersey site.
      




      Industry news:
      




      The Supreme Court declined to review an appeals court ruling that struck down key parts of an Oklahoma law regulating the retail networks created by pharmacy benefit managers.
      




      The California Attorney General’s office announced a $1.55 million settlement with Healthline Media LLC for alleged violations of the CCPA and UCL.
      




      The Department of Justice announced the results of its 2025 National Health Care Fraud Takedown, the largest in its history, with actions to disrupt healthcare fraud schemes involving more than $14.6 billion in intended losses.
      




      Amgen‘s bemarituzumab significantly extends survival in advanced gastric cancer patients with FGFR2b overexpression, according to recent data.
      




      Moderna said its experimental influenza vaccine was found to be 26.6% more effective than a currently approved annual flu shot when tested in adults aged 50 years and older in a late-stage study.
      




      Hikma Pharmaceuticals pledged $1 billion to expand its U.S. manufacturing presence.
      




      Pfizer ended a Phase 2 trial of maplirpacept, acquired from its $2.3 billion acquisition of Trillium Therapeutics due to recruitment issues.
      




      San Francisco startup Chai Discovery announced its newest AI models produced de novo antibodies in the lab with far greater success rates than others.
      




      Gilead Sciences terminated two Phase 2 studies of an RSV treatment candidate called obeldesivir.
      




      Senate Republicans’ version of President Donald Trump’s tax bill would lead to 11.8 million people losing health insurance over the next decade, according to a recent report from the Congressional Budget Office.
      




      Athelas launched its electronic health record.
      




      Beckley Psytech said its intranasal treatment aced a Phase 2b trial of patients with treatment-resistant depression.
      




      Arcturus said a Phase 2 mRNA therapeutic program achieved its goals in a rare disease population but investors were largely indifferent. 
      




      The BAM Connection took on creative duties for Rohto Eye Drops brands and will be responsible for strategy, all social, as well as sampling, partnership opportunities and media.
      




      See last week’s edition of Rx Rundown.